I agree to receive at most monthly updates on similar research. I retain all GDPR rights. CareAcross will never share my email address. The main question it aims to answer is whether progression free survival kann be prolonged with the addition of Acalabrutinib. Criteria for eligibility: Criteria: Inclusion Criteria: Informed consent 1. Ability to understand the purpose and risks of the study and capable of giving signed informed consent which includes: 1. Compliance with the requirements and restrictions listed in the informed consent form ICF.
Provision of signed and dated, written ICF prior to any mandatory study specific procedures, sampling, and analyses 3. Willing and able to participate in all required evaluations and procedures in this study protocol, including swallowing capsules and tablets without difficulty. Male patients who are sexually active with women of childbearing potential definitions see section Female patients of childbearing potential definitions see Disease characteristics 7.
DLBCL associated with chronic inflammation Meet the following laboratory parameters: 1. Exclusion Criteria: Medical conditions 1.
Evidence of disease such as severe or uncontrolled systemic diseases, including uncontrolled hypertension and renal transplant that, in the investigator's opinion, make it undesirable for the patient to participate in the study or that would jeopardize compliance with the protocol [e.
Jacquemin-Fink rheinlandklinikum. Coordination uniklinik-ulm. We use Cookies to deliver a better service to you. To hear about similar clinical trials, please enter your email below. Login to your account. Remember me.
